EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
Renalytix AI plc to develop Artificial Intelligence for early identification and management of kidney disease.
Annual Report and Accounts for the year ended 31 December 2017 now available.
EKF announces US Food and Drug Administration 510(k) clearance and CLIA waiver for DiaSpect Tm.
Notification of major holdings.
EKF Diagnostics announces its final results for the year ended 31 December 2017.
EKF Diagnostics announces that it will release its preliminary results for the year ended 31 December 2017 on Wednesday 14 March 2018.
EKF Diagnostics provides shareholders with the following update on current trading.
As at 29 December 2017, the Company's total issued share capital consists of 457,554,636 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company holds no Ordinary Shares in treasury.
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed medical diagnostics business, refers to its announcement dated 3 October 2017 (the "Previous Announcement") and confirms that with effect from 22 December 2017 it will cancel 78,113 of the 205,561 Compensation Shares (as defined in the Previous Announcement (the "Cancellation").